These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29471908)

  • 1. Prognostic factors for treatment success in patients with multidrug-resistant tuberculosis in China.
    Fan YM; Ding SP; Bao ZJ; Wu LM; Zhen LB; Xia Q; Zhu M
    Int J Tuberc Lung Dis; 2018 Mar; 22(3):300-305. PubMed ID: 29471908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China.
    Yu X; Zeng X; Shi W; Hu Y; Nie W; Chu N; Huang H
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013.
    Zhang L; Meng Q; Chen S; Zhang M; Chen B; Wu B; Yan G; Wang X; Jia Z
    Clin Microbiol Infect; 2018 Apr; 24(4):381-388. PubMed ID: 28712668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
    Prasad R; Verma SK; Sahai S; Kumar S; Jain A
    Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic.
    Dhingra VK; Rajpal S; Mittal A; Hanif M
    Indian J Tuberc; 2008 Jan; 55(1):15-21. PubMed ID: 18361306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Survival time and influencing factors in multidrug-resistant tuberculosis patients in Wuhan, 2006-2014].
    Wang JJ; Zhou ML; Chen C; Wu G; Zuo YP; Ren X; Chen Z; Wang WH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Nov; 40(11):1409-1413. PubMed ID: 31838813
    [No Abstract]   [Full Text] [Related]  

  • 9. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China.
    Xu C; Pang Y; Li R; Ruan Y; Wang L; Chen M; Zhang H
    J Infect; 2018 Apr; 76(4):348-353. PubMed ID: 29374587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
    J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India.
    Andries A; Isaakidis P; Das M; Khan S; Paryani R; Desai C; Dalal A; Mansoor H; Verma R; Fernandes D; Sotgiu G; Migliori GB; Saranchuk P
    PLoS One; 2013; 8(10):e78313. PubMed ID: 24194919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis.
    Bastos ML; Cosme LB; Fregona G; do Prado TN; Bertolde AI; Zandonade E; Sanchez MN; Dalcolmo MP; Kritski A; Trajman A; Maciel ELN
    BMC Infect Dis; 2017 Nov; 17(1):718. PubMed ID: 29137626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt.
    Gadallah MA; Mokhtar A; Rady M; El-Moghazy E; Fawzy M; Kandil SK
    J Formos Med Assoc; 2016 Nov; 115(11):997-1003. PubMed ID: 26696497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran.
    Mirsaeidi SM; Tabarsi P; Khoshnood K; Pooramiri MV; Rowhani-Rahbar A; Mansoori SD; Masjedi H; Zahirifard S; Mohammadi F; Farnia P; Masjedi MR; Velayati AA
    Int J Infect Dis; 2005 Nov; 9(6):317-22. PubMed ID: 16183321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-risk screening and detection of multidrug-resistant tuberculosis in two prefectures of China: a drug susceptibility surveillance-based secondary data analysis.
    Yang Z; Zhou C; Ning Z; Lu W; Zhao Q; Hu Y; Diwan VK; Xu B
    Glob Health Action; 2018; 11(1):1500763. PubMed ID: 30203719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to sputum culture conversion and its predictors among patients with multidrug-resistant tuberculosis in Hangzhou, China: A retrospective cohort study.
    Li Q; Lu M; Hsieh E; Wu L; Wu Y; Wang M; Wang L; Zhao G; Xie L; Qian HZ
    Medicine (Baltimore); 2020 Dec; 99(50):e23649. PubMed ID: 33327347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
    Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A
    Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid function in multidrug-resistant tuberculosis patients with or without human immunodeficiency virus (HIV) infection before commencement of MDR-TB drug regimen.
    Ige OM; Akinlade KS; Rahamon SK; Edem VF; Arinola OG
    Afr Health Sci; 2016 Jun; 16(2):596-602. PubMed ID: 27605977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia.
    Alene KA; Viney K; McBryde ES; Tsegaye AT; Clements AC
    Trop Med Int Health; 2017 Mar; 22(3):351-362. PubMed ID: 27978594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.